Boston Scientific Corporation

Boston Scientific Corporation develops, manufactures, and markets medical devices used across a wide range of interventional specialties. The company’s portfolio is built around less-invasive therapies that help physicians diagnose and treat disease while reducing the need for traditional surgery. Its products are sold globally to hospitals, clinics, outpatient facilities, and physician offices, with a large share of sales influenced by hospital purchasing groups and reimbursement dynamics. Over more than 45 years in medical technology, Boston Scientific has built a business centered on continuous product innovation, clinical evidence, and broad commercial reach.

24,8 %

69,0 %

14,4 %

+19,9 %

1.62

1.08

— Boston Scientific Corporation
%
Cardiovascular45% Devices used in interventional cardiology, electrophysiology, and peripheral vascular procedures.
Endoscopy20% Tools and systems used to diagnose and treat gastrointestinal and other conditions through minimally invasive procedures.
Urology and Pelvic Health15% Products for urinary tract, kidney stone, and pelvic floor-related procedures and therapies.
Neuromodulation10% Implantable and related therapies used to manage chronic pain and other neurological conditions.
Oncology and Embolization10% Therapies and devices for cancer treatment, including liver cancer and embolization procedures.

Boston Scientific sells primarily to healthcare providers that perform interventional procedures, including hospitals,...

  • Hospitals and health systemsprimary

    Buy the core interventional device portfolio for procedure rooms and specialty departments because they need reliable clinical outcomes and broad product availability.

  • Physicians and specialist cliniciansprimary

    Influence product choice in cardiology, endoscopy, urology, and oncology based on ease of use, efficacy, and training support.

  • Outpatient facilities and ambulatory surgery centerssecondary

    Purchase devices for procedures migrating out of inpatient settings, where efficiency and reimbursement economics are critical.

  • Group purchasing organizations and hospital networkssecondary

    Negotiate contracts and pricing across consolidated provider systems, affecting access and average selling prices.

  • International distributorsemerging

    Buy and resell products in selected markets where Boston Scientific does not maintain a direct commercial footprint.

Boston Scientific is a global business with products marketed in 127 countries. The company says the majority of net...

  • Operates in 127 countries through direct sales and distributors
  • United States is the largest and most strategically important market
  • Direct sales organizations support most net sales in core markets
  • Distributors are used where direct presence is not economical or strategic
  • China is a competitive hotspot with strong local suppliers
  • Global exposure increases sensitivity to reimbursement and tendering rules

Boston Scientific’s strategy is centered on five stated imperatives: strengthen category leadership, expand into...

01
Strengthen category leadershipshort-term

Core franchises provide the scale, clinical credibility, and commercial leverage that support repeat purchasing and hospital access.

02
Expand into high-growth adjacenciesmedium-term

Adjacent categories can reuse the company’s sales channels and clinical relationships while broadening growth beyond mature lines.

03
Drive global expansionmedium-term

International markets increase the addressable customer base and reduce dependence on any single healthcare system.

04
Develop key capabilitieslong-term

Digital, regulatory, and operational capabilities are increasingly important in a device market shaped by AI, cybersecurity, and evidence requirements.

Boston Scientific faces intense competition across its product lines, including pressure from large diversified device...

high

Competitive pricing pressure and market share loss

The company competes against large diversified device makers, niche specialists, and low-cost entrants, which can force concessions and reduce average selling prices.

Scope
Core interventional device franchises
Materiality
high
high

Regulatory and reimbursement changes

Approval pathways and payer coverage determine whether new devices can launch and how quickly procedures are adopted.

Scope
U.S., EU, and other major healthcare markets
Materiality
high
high

Litigation and product liability

Medical device companies face claims tied to product performance, compliance, and patient outcomes, which can create legal costs and provisions.

Scope
Global operations and legacy product lines
Materiality
high
high

Cybersecurity and IT/OT disruption

Manufacturing, shipping, and sensitive data systems depend on secure global infrastructure that can be targeted by malicious actors.

Scope
Enterprise systems and connected operations
Materiality
high
medium

China and local-supplier competition

Domestic competitors in China may benefit from local procurement preferences and pricing advantages.

Scope
International sales in China
Materiality
medium
Revenue recognition and deferred revenue
Quarterly comparability and reported net sales
Goodwill and intangible asset impairment
Potential non-cash charges to earnings
Legal and product liability accruals
Earnings volatility and cash outflows
Inventory provisions
Gross margin and operating profit
Non-GAAP adjustments
Adjusted earnings versus GAAP earnings

: 11/08/2026